

SEP. 3 (WED) - 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

Minsu Kang • Name:

• Current Position & Affiliation: Assistant Professor,

Division of Hematology and Medical Oncology Seoul National University Bundang Hospital

Korea • Country:

Educational Background:

Hanyang University Mar. 2013 - Feb. 2017

Medicine (M.D.)

Seoul National University Mar. 2005 - Feb. 2012

Electrical Engineering (B.S.)

• Professional Experience:

Seoul National University Bundang Hospital Aug. 2023 - Present

Assistant Professor in Division of Hematology and Medical Oncology

Seoul National University Bundang Hospital Mar. 2022 – Jul. 2023

Medical Oncologist in Division of Hematology and Medical Oncology

Seoul National University Hospital Mar. 2021 - Feb. 2022

Clinical Fellow in Division of Hematology and Medical Oncology

Seoul National University Bundang Hospital Mar. 2018 - Feb. 2021

Resident Physician in Department of Internal Medicine

Hanyang University Hospital Mar. 2017 - Feb. 2018

Intern

• Professional Organizations:

Korean Medical Association (KMA)

Korean Association of Internal Medicine (KAIM)

Korean Cancer Association (KCA)

Korean Cancer Study Group (KCSG)

Korean Association of Clinical Oncology (KSMO)

American Association for Cancer Research (AACR)

European Society of Medical Oncology (ESMO)

• Main Scientific Publications:

Hyung J, Kang M (co-first author), Kim I, Kim KP, Ryoo BY, Cheon J, Ryu H, Lee JS, Kim JW, Choi IS, Park JH, Abou-Alfa GK, Kim JW, Yoo C. Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-





SEP. 3 (WED) - 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

Analysis Based on Individual Patient-Level Data of Randomized Trials. Cancer Res Treat. 2024 Oct 17. doi: 10.4143/crt.2024.652. Epub ahead of print. PMID: 39438001.

Choi S, <u>Kang M (co-first author)</u>, Kim JW, Kim JW, Jeon JH, Oh HK, Lee HW, Cho JY, Kim DW, Cho S, Kim JH, Kim K, Kang SB, Jheon S, Lee KW. Long-term clinical outcomes after the second metastasectomy in patients with resected metastatic colorectal cancer. Curr Probl Cancer. 2024 Oct 22;53:101151. doi: 10.1016/j.currproblcancer.2024.101151. Epub ahead of print. PMID: 39442487.

<u>Kang M</u>, Na HY, Ahn S, Kim JW, Lee S, Ahn S, Lee JH, Youk J, Kim HT, Kim KJ, Suh KJ, Lee JS, Kim SH, Kim JW, Kim YJ, Lee KW, Yoon YS, Kim JH, Chung JH, Han HS, Lee JS. Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors. Elife. 2022 Dec 8;11:e78636. doi: 10.7554/eLife.78636. PMID: 36476508; PMCID: PMC9771369.

<u>Kang M</u>, Suh KJ, Kim JW, Byun JM, Kim JW, Lee JY, Lee JO, Bang SM, Kim YJ, Kim SH, Kim JH, Lee JS, Lee KW. Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. PLoS One. 2022 Jan 18;17(1):e0261671. doi: 10.1371/journal.pone.0261671. PMID: 35041664; PMCID: PMC8765650.

<u>Kang M</u>, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res. 2021 Feb;10(2):699-711. doi: 10.21037/tlcr-20-893. PMID: 33718015; PMCID: PMC7947423.

